This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity, according to investigators.
High fluctuations (in the top 25%) in total cholesterol were associated with a 60% increase in dementia and a 23% increase in cognitive decline.
The system, currently in early development in Japan, could minimize the need for blood tests, blood pressure cuffs, or expensive wearable devices.
The global temperature has risen by an average of 0.11° Fahrenheit per decade since 1850, or about 2 degrees in total.
Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP will be moderating a session about social determinants of health and heart failure.
Community pharmacists are playing an increasing role in sexual and reproductive health services and can provide that trustworthy information to patients.
Blaine Groat, PharmD, discusses the evolution of US Pharmacopeia (USP)'s drug standards, highlighting new compounding guidelines, as well as USP’s commitment to pharmacogenomics and upcoming opportunities for experts to contribute to personalized medicine standards.
The sessions will include late-breaking science, clinical practice guidelines, early innovators spotlight sessions, and more.
The 2024 American Association of Colleges of Pharmacy Annual Meeting took place from July 20 to July 23, 2024, in Boston, Massachusetts.
Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.
ASCO is prioritizing the expansion of pharmacist involvement in its organization by recognizing pharmacists' contributions to safety standards, quality improvement initiatives, and certification programs.
Gut microbiome research is no longer an obscure field in cancer care.
Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.
Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.
Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.
The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.
This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.
Liz Vogel, CPhT-Adv, CSPT, discusses the procedures and best practices for safe compounding of hazardous and non-hazardous drugs.
The investigators note that these findings are significant because bile duct cancer is a rare disease with limited treatments and low survival rates.
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely known as treatments for type 2 diabetes, though some have been approved for indications beyond diabetes.
Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.
Nearly 19,000 independent pharmacies continue to work across the country, with more than 200,000 employees and millions of patients.
Nationally, 7 million women live in maternal health deserts, defined as counties with limited or no available obstetric care.
Changing the way pharmacists and pharmacy staff think about themselves is key, although providers, payers, and patients must also change how they view the value of pharmacy services.
With COVID-19, influenza, respiratory syncytial virus (RSV), and other viruses now circulating, the time for pharmacists to get up to date on the latest vaccine recommendations is now.
Nathan Vanderford, PhD, MBA speaks about barriers to cancer care access experienced by patients in rural communities.
Sara Rogers, PharmD, discusses the formation and goals of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) initiative, which seeks to standardize pharmacogenomic practices and improve clinical decision-making by establishing consensus across all stakeholders.
Ryan Nelson, PharmD, discusses the STRIPE Annual Meeting and Consensus Workshop’s focus on unifying pharmacogenetic guidelines across major organizations, such as the FDA, European Medicines Agency, Clinical Pharmacogenetics Implementation Consortium, and National Comprehensive Cancer Network.
Stephanie White, PharmD, CSP, is presenting at the NCODA Fall Summit in Orlando, Florida.
These therapies are being investigated in earlier lines, with several new treatments in development.
